Abstract: Tank tote bags for storing cylinders such as diving tanks, welding tanks, and medical tanks such as oxygen tanks, in separate compartments that can be arranged in either vertical upright positions or horizontal laid down positions. One bag version has two tanks that can be arranged side-by-side in a bag with a mesh material behind the tanks, an open front and open top, and horizontal and vertical straps for holding the tanks together and separate from one another. Another bag version has three tanks arranged in a triangular arrangement. And another version has five tanks arranged in a triangular configuration. A still another version has four tanks arranged in a stacked two by two arrangement in a bag with a closeable top. The bags can be used in pickup truck beds and boats, homes and garages. The bags can be lightweight and can be easily carried and handled by one hand and later folded into small compact spaces.

Abstract: This invention pertains to agonists that activate nuclear receptors. These agonists include an extension that contacts a region of the nuclear receptor outside the native ligand binding pocket. Methods for producing, identifying and designing such agonists are included along with nuclear receptor agonist complexes and libraries of agonists.

Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.

Abstract: Recombinant materials have been obtained which permit the production of bovine growth hormone in E. coli.

Abstract: The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The invention includes a method for identifying residues comprising a coactivator binding site for a nuclear receptor of interest. Also included is a method of identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor of interest. Agonists and antagonists of coactivator binding to nuclear receptors also are provided. The invention is exemplified by identification and manipulation of the coactivator binding site of the thyroid receptor (TR), and compounds that bind to this sites. The methods can be applied to other nuclear receptors including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR.

Abstract: Methods for screening, identifying and/or designing agents that modulate nuclear receptors are provided. These agents contact a site on a nuclear receptor involved in dimer/heterodimer formation, cofactor molecule interactions, and/or folding, which is termed the nuclear receptor dimer/heterodimer regulatory site (DHRS). Methods employing the DHRS are included, along with nuclear receptor:agent complexes and libraries of agents.

Abstract: This invention pertains to agonists that activate nuclear receptors. These agonists include an extension that contacts a region of the nuclear receptor outside the native ligand binding pocket. Methods for producing, identifying and designing such agonists are included along with nuclear receptor agonist complexes and libraries of agonists.

Abstract: A DNA comprising a deoxynucleotide sequence coding for bovine growth hormone is described. A transfer vector and an expression vector containing this DNA and microorganisms transformed by these vectors are also described.

Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.

Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.

Abstract: Containment racks for safely storing cylinders such as diving tanks, welding tanks, and medical tanks such as oxygen tanks, in vertical upright positions. A first version has a holder container for supporting up to six tanks in two rows of three tanks per row. Each of the tanks are held in cylindrical hollow supports having an open upper end for inserting an individual tank therein. Another version uses cylinders side by side to one another in a straight line, and a still another version has four cylinder holders in a rectangular configuration. The rack devices can be used in different combinations to store three, four, five, six, seven and eight cylinders at one time. The rack devices can be formed from materials such as plastics, resin, glass, composites, fiberglass, combinations thereof, and the like. Each of the rack versions can include rectangular frames about a mid central portion having through-holes therein for allowing the racks to be tied down when being used in pickup truck beds and boats.

Abstract: The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The invention includes a method for identifying residues comprising a coactivator binding site for a nuclear receptor of interest. Also included is a method of identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor of interest. Agonists and antagonists of coactivator binding to nuclear receptors also are provided. The invention is exemplified by identification and manipulation of the coactivator binding site of the thyroid receptor (TR), and compounds that bind to this sites. The methods can be applied to other nuclear receptors including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR.

Abstract: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.

Abstract: The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as “TR”). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.

Abstract: The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.

Abstract: Selective thyroid hormone agonists are disclosed that are highly selective for the TR.beta. subtype with high binding affinity. Methods of using such agonists and pharmaceutical compositions containing them are also disclosed, as are novel procedures for their preparation.

Abstract: Methods for treating minimal disease hepatitis B infection are disclosed. Minimal disease carriers are given thymosin .alpha.-1, or biologically active fragments or analogs thereof In this way, the indications of hepatitis B can be reduced or eliminated.

Abstract: A DNA which comprises a deoxynucleotide sequence coding for prolactin, particularly human prolactin, is described. A transfer vector and an expression vector containing this DNA and microorganisms transformed by these vectors are also described. A method for preparing a reverse transcript (cDNA) from a messenger RNA is also disclosed herein.The invention described herein was made in the course of, or under, a grant from the National Institutes of Health.

Abstract: A DNA sequence encoding bovine prolactin and optionally including condons for the preceding 10 amino acids is used to construct expression systems to obtain recombinant production of these proteins.

Abstract: DNA comprising the naturally occurring nucleotide sequence coding for amino acids 44-90 of .beta.-lipotropin and including the entire coding region for .beta.-endorphin with the exception of the C-terminal glutamine was modified, transferred to an expression transfer vector, and expressed as a fusion protein. The fusion protein was further modified in vitro to yield mature .beta.-endorphin. .beta.-endorphin was purified from a bacterial lysate. The structure and biological activity of the resulting product was proven by immunological assay, and by two independent assays designed to demonstrate biological activity.